Description
Booth Gardner Parkinson's Care Center is conducting a study to evaluate the clinical effects, safety and tolerability of ATH-1017 in subjects with Parkinson's disease dementia (PDD). ATH-1017 is an experimental treatment for Alzheimer's disease (AD) and Parkinson's disease dementia (PDD), formulated as a sterile solution for subcutaneous (SC) injection.
Currently enrolling
Who may be eligible to participate?
Male and female, 40 to 85 years with a confirmed diagnosis of probable idiopathic Parkinson's disease or probable LBD for at least 1 year.
What does participation involve?
- The study will be conducted on an outpatient basis.
- During the double-blind treatment period, clinic visits will take place on Day 1 and at Weeks 2, 6, 12, 16, 20, and 26, with a safety follow-up visit at Week 30.
- Study drug/placebo will be administered by subcutaneous (SC) injection once daily, preferably during daytime.
- Participants will receive 1 syringe/day of one of the following:
- 70 mg/ml of ATH-1017
- 40 mg/ml of ATH-1017
- placebo
My Navigator